First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab.
There is no standard chemotherapy regimen in advanced gastric cancer with poor performance status and hepatic dysfunction. New chemotherapeutical agents and targeted therapy have demonstrated promising results in terms of efficacy and safety in phase II clinical trials. We report the case of a 68-year-old man with stage IV gastric cancer and severe hepatic dysfunction due to liver metastases treated with a combination of oxaliplatin, 5-fluorouracil and cetuximab.
Muñoz Martín
Andrés Jesús
AJ
Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ajmunoz.hgugm@salud.madrid.org
Martínez Marín
Virginia
V
Arranz Cózar
Juan Luis
JL
Cabezón Gutiérrez
Luis
L
González del Val Subirats
Ricardo
R
García Alfonso
Pilar
P
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068818:Cetuximab; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068818:Cetuximab; D005472:Fluorouracil